Abstract:
OBJECTIVE To establish an HPLC method for the determination of mitotane in plasma and apply it to therapeutic drug monitoring in children.
METHODS An Agilent ZORBAX Eclipse XDB-C18(4.6 mm×150 mm, 5 μm) column was used. The mobile phase consisted of water and acetonitrile(15∶85) with isocratic elution. The flow rate was 1.0 mL·min−1, the column temperature was 35 ℃, and the detection wavelength was 230 nm.
RESULTS Mitotane showed good linearity within 1.0–50.0 μg·mL−1. The accuracy, precision, extraction recovery, and stability all met the guidance requirements. A total of 25 plasma samples from 7 adrenocortical carcinoma children were analyzed, with trough concentrations ranging from 1.19 to 27.30 μg·mL−1, only 8 samples(32%) had concentrations within the guideline-recommended therapeutic window, 14(56%) were below the recommended window(<14 μg·mL−1), and the remaining 3(12%) were above it. Among the 7 pediatric patients, 4 reached the therapeutic window after dose adjustment and management of adverse reactions, whereas 3 did not, as adverse reactions precluded further dose escalation.
CONCLUSION The HPLC method optimized in this study is simple to operate and stable, effectively meeting the detection requirements for accurate quantification of pediatric plasma mitotane concentrations during the dose-adjustment period. Pediatric patients show marked interindividual variability in mitotane concentrations and frequently develop adverse reactions, and the existing therapeutic window has limitations in guiding dose adjustment; therefore, long-term therapeutic drug monitoring should be implemented to optimize a pediatric-specific therapeutic window.